Disease · MONDO_0004728

diabetic macular edema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetic macular edema. Diseases, record MONDO_0004728. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004728

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetic macular edema; Open Targets
Open Targets ID: MONDO_0004728; Open Targets
Other names: DME; Open Targets
Disease Ontology: DOID:9191; Disease Ontology
Highest stage of its drugs: Approval, for 2 of its 89 drugs, from PMDA and TTD; Open Targets

Drugs89

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	PMDA	104	101	99	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Approval	TTD	20	18	18	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 3	ClinicalTrials.gov	81	81	77	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	47	47	43	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	39	39	39	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	30	30	29	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Phase 3	ClinicalTrials.gov and TTD	9	8	8	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CONBERCEPT	CHEMBL2108313	Protein	Phase 3	ClinicalTrials.gov and TTD	7	6	5	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets

1 to 10 of 89

See all 89 drugs

Targets116

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	VEGF-A mRNA	9	VEGF-A mRNA RNAi inhibitor; Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	6	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS2	Cyclooxygenase	6	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	5	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
EPOR	Erythropoietin receptor	4	Erythropoietin receptor agonist; Innate repair receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2057	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets
ANGPT2	Angiopoietin-2	2	Angiopoietin-2 inhibitor	Approval	https://conductscience.org/library/genes/285	Drugs and targets
CA2	Carbonic anhydrase 2	2	Carbonic anhydrase II inhibitor	Phase 2/3	https://conductscience.org/library/genes/760	Drugs and targets

1 to 10 of 116

See all 116 targets

Trials332

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04432831	A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema	Phase 3	1,479	2024-10-30	Diabetic Macular Edema	FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT00344968	Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema	Phase 3	956	2014-05-07	Diabetic Macular Edema	FLUOCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT03622593	A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema	Phase 3	951	2022-03-22	Diabetic Macular Edema	AFLIBERCEPT, FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT03622580	A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)	Phase 3	940	2022-03-22	Diabetic Macular Edema	AFLIBERCEPT, FARICIMAB	Its record names the disease	ClinicalTrials.gov
NCT00367133	Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema	Phase 3	840	2010-07-09	Diabetic Macular Edema	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00090519	Reduction in the Occurrence of Center-Involved Diabetic Macular Edema	Phase 3	731	2016-05-16	Diabetic Retinopathy	RUBOXISTAURIN	Its record names the disease	ClinicalTrials.gov
NCT01909791	Treatment for CI-DME in Eyes With Very Good VA Study	Phase 3	702	2020-01-03	Diabetic Macular Edema	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00444600	Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema	Phase 3	691	2011-07-12	Diabetic Retinopathy, Diabetic Macular Edema	RANIBIZUMAB, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00604383	Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study	Phase 3	685	2016-01-28	Diabetic Retinopathy	RUBOXISTAURIN	Its record names the disease	ClinicalTrials.gov
NCT01627249	Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema	Phase 3	660	2015-12-16	Diabetic Macular Edema	AFLIBERCEPT, BEVACIZUMAB, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 332

See all 332 trials

Comparisons in its trials88

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Studies KS301P104 and KS301P105 Combined	6 of 433	3 of 437	870	NCT04603937	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Studies KS301P104 and KS301P105 Combined	6 of 433	3 of 437	870	NCT04611152	Trial comparisons
Ruboxistaurin vs Placebo: serious adverse events	93 of 371	82 of 360	731	NCT00090519	Trial comparisons
Ruboxistaurin vs Placebo: serious adverse events	145 of 345	157 of 340	685	NCT00604383	Trial comparisons
Brolucizumab 6mg q4w vs Aflibercept 2mg q4w: Number of Subjects With Non-ocular AEs (Greater Than or Equal to 2% in Any Treatment Arm)	209 of 346	96 of 171	517	NCT03917472	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): deaths from any cause	5 of 230	5 of 230	460	NCT04611152	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): serious adverse events	61 of 230	51 of 230	460	NCT04611152	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): deaths from any cause	4 of 228	6 of 229	457	NCT04603937	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): serious adverse events	53 of 228	57 of 229	457	NCT04603937	Trial comparisons
KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Study KS301P105	6 of 218	3 of 218	436	NCT04603937	Trial comparisons

1 to 10 of 88

See all 88 comparisons in its trials

Papers from its trials196

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42058170	RESULT	1	PubMed
41534798	RESULT	3	PubMed
38158159	RESULT	2	PubMed
37007930	RESULT	1	PubMed
36309572	RESULT	1	PubMed
34967834	RESULT	1	PubMed
31037289	RESULT	1	PubMed
30584490	RESULT	1	PubMed
29470308	RESULT	1	PubMed
29127949	RESULT	2	PubMed

1 to 10 of 196

See all 196 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004728

GET https://conductscience.org/api/diseases/v1/MONDO_0004728/drugs?page=2

API reference For AI assistants